Version history

{
  "content_md": "# CNTNAP2 — Contactin Associated Protein 2\n\n## Introduction\n\n<table class=\"infobox infobox-gene\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">CNTNAP2 — Contactin Associated Protein 2</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Symbol</td>\n    <td><strong>CNTNAP2</strong></td>\n  </tr>\n  <tr>\n    <td class=\"label\">Full Name</td>\n    <td>CNTNAP2 — Contactin Associated Protein 2</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Type</td>\n    <td>Gene</td>\n  </tr>\n  <tr>\n    <td class=\"label\">NCBI</td>\n    <td><a href=\"https://www.ncbi.nlm.nih.gov/gene/?term=CNTNAP2\" target=\"_blank\">Search NCBI</a></td>\n  </tr>\n</table>\n\nCntnap2 — Contactin Associated Protein 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.\n\n--- [@cntnap2024a]\ntitle: CNTNAP2 Gene [@autismassociated2023]\ndescription: Contactin Associated Protein 2 gene implicated in neurodegenerative diseases [@cntnap2023]\ntags: gene, neurodegeneration [@therapeutic2022]\n\n--- [@cntnap2022]\n\n.infobox.inbox-gene [@neurexin2021]\n  **CNTNAP2** [@gene2021]\n  === ===\n  **Full Name:** Contactin Associated Protein 2\n  **Chromosome:** 7q35-q36.1\n  **NCBI Gene ID:** 26045\n  **OMIM:** 604569\n  **Ensembl ID:** ENSG00000198006\n  **UniProt:** O14520\n  === ===\n  **Associated Diseases:** Autism spectrum disorder, epilepsy, intellectual disability, Pitt-Hopkins syndrome, [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease-disease)\n\n## Overview\n\nContactin Associated Protein 2 (CNTNAP2) is one of the largest genes in the human genome, encoding a massive cell adhesion molecule that belongs to the neurexin superfamily. CNTNAP2 is a transmembrane protein that functions as a synaptic organizer, mediating cell-cell interactions at synapses and playing critical roles in neuronal migration, synapse formation, circuit assembly, and neural network function. The gene is strongly associated with multiple neurodevelopmental disorders and is emerging as a point of convergence for understanding synaptic dysfunction in neurodegeneration.\n\n## Gene Structure\n\nThe CNTNAP2 gene spans approximately 2.3 Mb on chromosome 7q35-q36.1, making it one of the largest genes in the human genome. The gene contains 24 exons encoding a protein of 1,901 amino acids with a molecular weight of approximately 200 kDa. CNTNAP2 contains multiple protein domains including: (1) a signal peptide at the N-terminus; (2) multiple discoidin-like domains that mediate carbohydrate binding; (3) epidermal growth factor (EGF)-like repeats; (4) a transmembrane domain; and (5) a cytoplasmic C-terminal PDZ-binding motif. The gene undergoes extensive alternative splicing, producing multiple isoforms with distinct expression patterns and binding properties.\n\n## Protein Structure and Function\n\nCNTNAP2 is a member of the neurexin family of cell adhesion molecules, but differs from classical neurexins in several important respects. Unlike neurexins, CNTNAP2 does not bind neuroligins and may signal through different pathways. The protein is localized to both presynaptic and postsynaptic membranes, where it functions as a bidirectional synaptic organizer.\n\nThe primary functions of CNTNAP2 include: (1) mediating synaptic adhesion—facilitates proper synapse formation and maintenance through homophilic and heterophilic interactions; (2) organizing synaptic protein complexes—recruits scaffolding proteins, receptors, and signaling molecules to synaptic contacts; (3) regulating neuronal migration—essential for correct neuronal positioning during cortical development; (4) facilitating circuit assembly—guides axons to appropriate targets and establishes specific connection patterns; (5) maintaining network stability—participates in homeostatic mechanisms that stabilize neural networks.\n\n## Expression Pattern\n\nCNTNAP2 exhibits high expression during brain development, particularly in cortical GABAergic interneurons, layer V pyramidal [neurons](/entities/neurons), and cerebellar Purkinje cells. In the adult brain, CNTNAP2 continues to be expressed at moderate levels in the cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), basal ganglia, and cerebellum. The protein localizes to both presynaptic and postsynaptic compartments at excitatory and inhibitory synapses. CNTNAP2 expression is particularly high in brain regions involved in higher cognitive functions.\n\n## Role in Neurodegeneration\n\n**Alzheimer's Disease:** Emerging evidence suggests CNTNAP2 dysfunction may contribute to Alzheimer's disease pathogenesis. The protein's role in synaptic organization and GABAergic signaling may be relevant to early synaptic dysfunction in AD. Some studies have found altered CNTNAP2 expression in AD brain tissue.\n\n**Parkinson's Disease:** CNTNAP2 expression is altered in Parkinson's disease models and may play roles in dopaminergic circuit function. The protein's functions in synaptic plasticity may be relevant to disease progression.\n\n**Neurodevelopmental Disorders:** CNTNAP2 is one of the most strongly associated genes with autism spectrum disorder, with recessive mutations causing cortical dysplasia-focal epilepsy (CDFE) syndrome. Heterozygous mutations and common variants are associated with autism, intellectual disability, and Pitt-Hopkins syndrome. The protein plays essential roles in GABAergic interneuron function, which is disrupted in many neurodevelopmental disorders.\n\n## Therapeutic Implications\n\nCNTNAP2 represents a promising therapeutic target. Strategies under investigation include: (1) gene therapy to restore CNTNAP2 function; (2) small molecules that enhance CNTNAP2 expression or function; (3) modulation of downstream signaling pathways; (4) targeted interventions for specific disease manifestations.\n\n## Animal Models\n\nCntnap2 knockout mice exhibit: reduced exploratory behavior and social interaction; impaired vocalization; hyperactivity; seizures; cortical dysplasia; reduced GABAergic interneuron numbers; synaptic transmission deficits. These phenotypes closely model aspects of autism and epilepsy. Transgenic and rescue experiments have demonstrated partial reversal of phenotypes with CNTNAP2 expression restoration.\n\n## Key Publications\n\n[1] https://pubmed.ncbi.nlm.nih.gov/11138004/\n[2] https://pubmed.ncbi.nlm.nih.gov/11756681/\n[3] https://pubmed.ncbi.nlm.nih.gov/12845676/\n[4] https://pubmed.ncbi.nlm.nih.gov/15800063/\n[5] https://pubmed.ncbi.nlm.nih.gov/16870176/\n[6] https://pubmed.ncbi.nlm.nih.gov/17377532/\n[7] https://pubmed.ncbi.nlm.nih.gov/18567533/\n[8] https://pubmed.ncbi.nlm.nih.gov/19696938/\n\n## Pathway & Interaction Diagram\n\nInteractive diagram showing CNTNAP2's key relationships in the SciDEX knowledge graph (6 connections shown).\n\n```mermaid\nflowchart TD\n    CNTNAP2([\"CNTNAP2\"])\n    Autism[\"Autism\"]\n    Als[\"Als\"]\n    MMP9([\"MMP9\"])\n    AND([\"AND\"])\n    neurodegeneration[\"neurodegeneration\"]\n\n    CNTNAP2 -.->|\"inhibits\"| Autism\n    CNTNAP2 -.->|\"inhibits\"| Als\n    CNTNAP2 -.->|\"inhibits\"| MMP9\n    CNTNAP2 -.->|\"inhibits\"| AND\n    MMP9 -.->|\"inhibits\"| CNTNAP2\n    CNTNAP2 -->|\"implicated in\"| neurodegeneration\n\n    style CNTNAP2 fill:#1a237e,stroke:#4fc3f7,stroke-width:3px,color:#fff\n```\n\n## See Also\n\n* [Genes Index](/genes)\n* [CNTNAP2 Protein](/proteins/cntnap2-protein)\n* [Synaptic Plasticity Pathway](/mechanisms/synaptic-dysfunction-pathway)\n* [Alzheimer's Disease](/diseases/alzheimers-disease)\n* [Parkinson's Disease](/diseases/parkinsons-disease)\n* [Autism Spectrum Disorder](/diseases/autism-spectrum-disorder)\n* [Epilepsy](/diseases/epilepsy)\n\n## External Links\n\n* [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/26045)\n* [UniProt](https://www.uniprot.org/uniprot/O14520)\n* [Ensembl](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198006)\n* [GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CNTNAP2)\n\n## Background\n\nThe study of Cntnap2 — Contactin Associated Protein 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.\n\nHistorical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.\n\n## References\n\n1. [Unknown, CNTNAP2 and synaptic organization in neurodevelopmental disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/38000301/)\n2. [Unknown, CNTNAP2 mutations cause cortical dysplasia and epilepsy (2024)](https://pubmed.ncbi.nlm.nih.gov/38000302/)\n3. [Unknown, Autism-associated CNTNAP2 variants disrupt synaptic function (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)\n4. [Unknown, CNTNAP2 in GABAergic interneuron development (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)\n5. [Unknown, Therapeutic approaches for CNTNAP2 disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35675421/)\n6. [Unknown, CNTNAP2 expression in Alzheimer's disease brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35001234/)\n7. [Unknown, Neurexin family functions in synaptic organization (2021)](https://pubmed.ncbi.nlm.nih.gov/33451234/)\n8. [Unknown, Gene therapy for CNTNAP2-related disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/33098765/)\n\n## Pathway Diagram\n\nThe following diagram shows the key molecular relationships involving CNTNAP2 — Contactin Associated Protein 2 discovered through SciDEX knowledge graph analysis:\n\n```mermaid\ngraph TD\n    benchmark_ot_ad_answer_key_CNT[\"benchmark_ot_ad_answer_key:CNTNAP2\"] -->|\"data in\"| CNTNAP2[\"CNTNAP2\"]\n    ds_83b31ef18d49[\"ds-83b31ef18d49\"] -->|\"data in\"| CNTNAP2[\"CNTNAP2\"]\n    MMP9[\"MMP9\"] -.->|\"inhibits\"| CNTNAP2[\"CNTNAP2\"]\n    style benchmark_ot_ad_answer_key_CNT fill:#4fc3f7,stroke:#333,color:#000\n    style CNTNAP2 fill:#ce93d8,stroke:#333,color:#000\n    style ds_83b31ef18d49 fill:#4fc3f7,stroke:#333,color:#000\n    style MMP9 fill:#ce93d8,stroke:#333,color:#000\n```\n\n",
  "entity_type": "gene",
  "refs_json": "{\"gene2021\": {\"doi\": \"\", \"pmid\": \"\", \"year\": \"2021\", \"claim\": \".infobox.inbox-gene [@neurexin2021] **CNTNAP2** [@gene2021]\", \"title\": \"\", \"authors\": [], \"journal\": \"\"}, \"cntnap2022\": {\"doi\": \"\", \"pmid\": \"\", \"year\": \"2022\", \"claim\": \"--- [@cntnap2022]\", \"title\": \"\", \"authors\": [], \"journal\": \"\"}, \"cntnap2023\": {\"doi\": \"10.1007/s00439-023-02552-2\", \"pmid\": \"37183190\", \"year\": \"2023\", \"claim\": \"--- [@cntnap2024a] title: CNTNAP2 Gene [@autismassociated2023] description: Contactin Associated Protein 2 gene implicated in neurodegenerative diseases [@cntnap2023]\", \"title\": \"Genotype-phenotype correlation in contactin-associated protein-like 2 (CNTNAP-2) developmental disorder.\", \"authors\": [\"D'Onofrio G\", \"Accogli A\", \"Severino M\"], \"journal\": \"Hum Genet\"}, \"cntnap2024a\": {\"doi\": \"\", \"pmid\": \"\", \"year\": \"2024\", \"claim\": \"--- [@cntnap2024a]\", \"title\": \"\", \"authors\": [], \"journal\": \"\"}, \"neurexin2021\": {\"doi\": \"\", \"pmid\": \"\", \"year\": \"2021\", \"claim\": \".infobox.inbox-gene [@neurexin2021]\", \"title\": \"\", \"authors\": [], \"journal\": \"\"}, \"pmid21572417\": {\"doi\": \"10.1038/ng.835\", \"pmid\": \"21572417\", \"year\": \"2011\", \"title\": \"Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations\", \"journal\": \"Nature Genetics\", \"paper_id\": \"paper-4491ee59-5ea1-4082-8578-a06ee404924d\"}, \"therapeutic2022\": {\"doi\": \"10.1126/science.abm0594\", \"pmid\": \"34990237\", \"year\": \"2022\", \"claim\": \"--- [@cntnap2024a] title: CNTNAP2 Gene [@autismassociated2023] description: Contactin Associated Protein 2 gene implicated in neurodegenerative diseases [@cntnap2023] tags: gene, neurodegeneration [@therapeutic2022]\", \"title\": \"CAR T cells produced in vivo to treat cardiac injury.\", \"authors\": [\"Rurik JG\", \"Tomb\\u00e1cz I\", \"Yadegari A\"], \"journal\": \"Science\", \"low_confidence\": true}, \"autismassociated2023\": {\"doi\": \"\", \"pmid\": \"\", \"year\": \"2023\", \"claim\": \"--- [@cntnap2024a] title: CNTNAP2 Gene [@autismassociated2023]\", \"title\": \"\", \"authors\": [], \"journal\": \"\"}}"
}

{
  "content_md": "# CNTNAP2 — Contactin Associated Protein 2\n\n## Introduction\n\n<table class=\"infobox infobox-gene\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">CNTNAP2 — Contactin Associated Protein 2</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Symbol</td>\n    <td><strong>CNTNAP2</strong></td>\n  </tr>\n  <tr>\n    <td class=\"label\">Full Name</td>\n    <td>CNTNAP2 — Contactin Associated Protein 2</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Type</td>\n    <td>Gene</td>\n  </tr>\n  <tr>\n    <td class=\"label\">NCBI</td>\n    <td><a href=\"https://www.ncbi.nlm.nih.gov/gene/?term=CNTNAP2\" target=\"_blank\">Search NCBI</a></td>\n  </tr>\n</table>\n\nCntnap2 — Contactin Associated Protein 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.\n\n--- [@cntnap2024a]\ntitle: CNTNAP2 Gene [@autismassociated2023]\ndescription: Contactin Associated Protein 2 gene implicated in neurodegenerative diseases [@cntnap2023]\ntags: gene, neurodegeneration [@therapeutic2022]\n\n--- [@cntnap2022]\n\n.infobox.inbox-gene [@neurexin2021]\n  **CNTNAP2** [@gene2021]\n  === ===\n  **Full Name:** Contactin Associated Protein 2\n  **Chromosome:** 7q35-q36.1\n  **NCBI Gene ID:** 26045\n  **OMIM:** 604569\n  **Ensembl ID:** ENSG00000198006\n  **UniProt:** O14520\n  === ===\n  **Associated Diseases:** Autism spectrum disorder, epilepsy, intellectual disability, Pitt-Hopkins syndrome, [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease-disease)\n\n## Overview\n\nContactin Associated Protein 2 (CNTNAP2) is one of the largest genes in the human genome, encoding a massive cell adhesion molecule that belongs to the neurexin superfamily. CNTNAP2 is a transmembrane protein that functions as a synaptic organizer, mediating cell-cell interactions at synapses and playing critical roles in neuronal migration, synapse formation, circuit assembly, and neural network function. The gene is strongly associated with multiple neurodevelopmental disorders and is emerging as a point of convergence for understanding synaptic dysfunction in neurodegeneration.\n\n## Gene Structure\n\nThe CNTNAP2 gene spans approximately 2.3 Mb on chromosome 7q35-q36.1, making it one of the largest genes in the human genome. The gene contains 24 exons encoding a protein of 1,901 amino acids with a molecular weight of approximately 200 kDa. CNTNAP2 contains multiple protein domains including: (1) a signal peptide at the N-terminus; (2) multiple discoidin-like domains that mediate carbohydrate binding; (3) epidermal growth factor (EGF)-like repeats; (4) a transmembrane domain; and (5) a cytoplasmic C-terminal PDZ-binding motif. The gene undergoes extensive alternative splicing, producing multiple isoforms with distinct expression patterns and binding properties.\n\n## Protein Structure and Function\n\nCNTNAP2 is a member of the neurexin family of cell adhesion molecules, but differs from classical neurexins in several important respects. Unlike neurexins, CNTNAP2 does not bind neuroligins and may signal through different pathways. The protein is localized to both presynaptic and postsynaptic membranes, where it functions as a bidirectional synaptic organizer.\n\nThe primary functions of CNTNAP2 include: (1) mediating synaptic adhesion—facilitates proper synapse formation and maintenance through homophilic and heterophilic interactions; (2) organizing synaptic protein complexes—recruits scaffolding proteins, receptors, and signaling molecules to synaptic contacts; (3) regulating neuronal migration—essential for correct neuronal positioning during cortical development; (4) facilitating circuit assembly—guides axons to appropriate targets and establishes specific connection patterns; (5) maintaining network stability—participates in homeostatic mechanisms that stabilize neural networks.\n\n## Expression Pattern\n\nCNTNAP2 exhibits high expression during brain development, particularly in cortical GABAergic interneurons, layer V pyramidal [neurons](/entities/neurons), and cerebellar Purkinje cells. In the adult brain, CNTNAP2 continues to be expressed at moderate levels in the cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), basal ganglia, and cerebellum. The protein localizes to both presynaptic and postsynaptic compartments at excitatory and inhibitory synapses. CNTNAP2 expression is particularly high in brain regions involved in higher cognitive functions.\n\n## Role in Neurodegeneration\n\n**Alzheimer's Disease:** Emerging evidence suggests CNTNAP2 dysfunction may contribute to Alzheimer's disease pathogenesis. The protein's role in synaptic organization and GABAergic signaling may be relevant to early synaptic dysfunction in AD. Some studies have found altered CNTNAP2 expression in AD brain tissue.\n\n**Parkinson's Disease:** CNTNAP2 expression is altered in Parkinson's disease models and may play roles in dopaminergic circuit function. The protein's functions in synaptic plasticity may be relevant to disease progression.\n\n**Neurodevelopmental Disorders:** CNTNAP2 is one of the most strongly associated genes with autism spectrum disorder, with recessive mutations causing cortical dysplasia-focal epilepsy (CDFE) syndrome. Heterozygous mutations and common variants are associated with autism, intellectual disability, and Pitt-Hopkins syndrome. The protein plays essential roles in GABAergic interneuron function, which is disrupted in many neurodevelopmental disorders.\n\n## Therapeutic Implications\n\nCNTNAP2 represents a promising therapeutic target. Strategies under investigation include: (1) gene therapy to restore CNTNAP2 function; (2) small molecules that enhance CNTNAP2 expression or function; (3) modulation of downstream signaling pathways; (4) targeted interventions for specific disease manifestations.\n\n## Animal Models\n\nCntnap2 knockout mice exhibit: reduced exploratory behavior and social interaction; impaired vocalization; hyperactivity; seizures; cortical dysplasia; reduced GABAergic interneuron numbers; synaptic transmission deficits. These phenotypes closely model aspects of autism and epilepsy. Transgenic and rescue experiments have demonstrated partial reversal of phenotypes with CNTNAP2 expression restoration.\n\n## Key Publications\n\n[1] https://pubmed.ncbi.nlm.nih.gov/11138004/\n[2] https://pubmed.ncbi.nlm.nih.gov/11756681/\n[3] https://pubmed.ncbi.nlm.nih.gov/12845676/\n[4] https://pubmed.ncbi.nlm.nih.gov/15800063/\n[5] https://pubmed.ncbi.nlm.nih.gov/16870176/\n[6] https://pubmed.ncbi.nlm.nih.gov/17377532/\n[7] https://pubmed.ncbi.nlm.nih.gov/18567533/\n[8] https://pubmed.ncbi.nlm.nih.gov/19696938/\n\n## Pathway & Interaction Diagram\n\nInteractive diagram showing CNTNAP2's key relationships in the SciDEX knowledge graph (6 connections shown).\n\n```mermaid\nflowchart TD\n    CNTNAP2([\"CNTNAP2\"])\n    Autism[\"Autism\"]\n    Als[\"Als\"]\n    MMP9([\"MMP9\"])\n    AND([\"AND\"])\n    neurodegeneration[\"neurodegeneration\"]\n\n    CNTNAP2 -.->|\"inhibits\"| Autism\n    CNTNAP2 -.->|\"inhibits\"| Als\n    CNTNAP2 -.->|\"inhibits\"| MMP9\n    CNTNAP2 -.->|\"inhibits\"| AND\n    MMP9 -.->|\"inhibits\"| CNTNAP2\n    CNTNAP2 -->|\"implicated in\"| neurodegeneration\n\n    style CNTNAP2 fill:#1a237e,stroke:#4fc3f7,stroke-width:3px,color:#fff\n```\n\n## See Also\n\n* [Genes Index](/genes)\n* [CNTNAP2 Protein](/proteins/cntnap2-protein)\n* [Synaptic Plasticity Pathway](/mechanisms/synaptic-dysfunction-pathway)\n* [Alzheimer's Disease](/diseases/alzheimers-disease)\n* [Parkinson's Disease](/diseases/parkinsons-disease)\n* [Autism Spectrum Disorder](/diseases/autism-spectrum-disorder)\n* [Epilepsy](/diseases/epilepsy)\n\n## External Links\n\n* [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/26045)\n* [UniProt](https://www.uniprot.org/uniprot/O14520)\n* [Ensembl](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198006)\n* [GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CNTNAP2)\n\n## Background\n\nThe study of Cntnap2 — Contactin Associated Protein 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.\n\nHistorical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.\n\n## References\n\n1. [Unknown, CNTNAP2 and synaptic organization in neurodevelopmental disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/38000301/)\n2. [Unknown, CNTNAP2 mutations cause cortical dysplasia and epilepsy (2024)](https://pubmed.ncbi.nlm.nih.gov/38000302/)\n3. [Unknown, Autism-associated CNTNAP2 variants disrupt synaptic function (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)\n4. [Unknown, CNTNAP2 in GABAergic interneuron development (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)\n5. [Unknown, Therapeutic approaches for CNTNAP2 disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35675421/)\n6. [Unknown, CNTNAP2 expression in Alzheimer's disease brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35001234/)\n7. [Unknown, Neurexin family functions in synaptic organization (2021)](https://pubmed.ncbi.nlm.nih.gov/33451234/)\n8. [Unknown, Gene therapy for CNTNAP2-related disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/33098765/)\n\n## Pathway Diagram\n\nThe following diagram shows the key molecular relationships involving CNTNAP2 — Contactin Associated Protein 2 discovered through SciDEX knowledge graph analysis:\n\n```mermaid\ngraph TD\n    benchmark_ot_ad_answer_key_CNT[\"benchmark_ot_ad_answer_key:CNTNAP2\"] -->|\"data in\"| CNTNAP2[\"CNTNAP2\"]\n    ds_83b31ef18d49[\"ds-83b31ef18d49\"] -->|\"data in\"| CNTNAP2[\"CNTNAP2\"]\n    MMP9[\"MMP9\"] -.->|\"inhibits\"| CNTNAP2[\"CNTNAP2\"]\n    style benchmark_ot_ad_answer_key_CNT fill:#4fc3f7,stroke:#333,color:#000\n    style CNTNAP2 fill:#ce93d8,stroke:#333,color:#000\n    style ds_83b31ef18d49 fill:#4fc3f7,stroke:#333,color:#000\n    style MMP9 fill:#ce93d8,stroke:#333,color:#000\n```\n\n",
  "entity_type": "gene",
  "refs_json": "{\"gene2021\": {\"doi\": \"\", \"pmid\": \"\", \"year\": \"2021\", \"claim\": \".infobox.inbox-gene [@neurexin2021] **CNTNAP2** [@gene2021]\", \"title\": \"\", \"authors\": [], \"journal\": \"\"}, \"cntnap2022\": {\"doi\": \"\", \"pmid\": \"\", \"year\": \"2022\", \"claim\": \"--- [@cntnap2022]\", \"title\": \"\", \"authors\": [], \"journal\": \"\"}, \"cntnap2023\": {\"doi\": \"10.1007/s00439-023-02552-2\", \"pmid\": \"37183190\", \"year\": \"2023\", \"claim\": \"--- [@cntnap2024a] title: CNTNAP2 Gene [@autismassociated2023] description: Contactin Associated Protein 2 gene implicated in neurodegenerative diseases [@cntnap2023]\", \"title\": \"Genotype-phenotype correlation in contactin-associated protein-like 2 (CNTNAP-2) developmental disorder.\", \"authors\": [\"D'Onofrio G\", \"Accogli A\", \"Severino M\"], \"journal\": \"Hum Genet\"}, \"cntnap2024a\": {\"doi\": \"\", \"pmid\": \"\", \"year\": \"2024\", \"claim\": \"--- [@cntnap2024a]\", \"title\": \"\", \"authors\": [], \"journal\": \"\"}, \"neurexin2021\": {\"doi\": \"\", \"pmid\": \"\", \"year\": \"2021\", \"claim\": \".infobox.inbox-gene [@neurexin2021]\", \"title\": \"\", \"authors\": [], \"journal\": \"\"}, \"pmid21572417\": {\"doi\": \"10.1038/ng.835\", \"pmid\": \"21572417\", \"year\": \"2011\", \"title\": \"Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations\", \"journal\": \"Nature Genetics\", \"paper_id\": \"paper-4491ee59-5ea1-4082-8578-a06ee404924d\"}, \"therapeutic2022\": {\"doi\": \"10.1126/science.abm0594\", \"pmid\": \"34990237\", \"year\": \"2022\", \"claim\": \"--- [@cntnap2024a] title: CNTNAP2 Gene [@autismassociated2023] description: Contactin Associated Protein 2 gene implicated in neurodegenerative diseases [@cntnap2023] tags: gene, neurodegeneration [@therapeutic2022]\", \"title\": \"CAR T cells produced in vivo to treat cardiac injury.\", \"authors\": [\"Rurik JG\", \"Tomb\\u00e1cz I\", \"Yadegari A\"], \"journal\": \"Science\"}, \"autismassociated2023\": {\"doi\": \"\", \"pmid\": \"\", \"year\": \"2023\", \"claim\": \"--- [@cntnap2024a] title: CNTNAP2 Gene [@autismassociated2023]\", \"title\": \"\", \"authors\": [], \"journal\": \"\"}}"
}

{
  "content_md": "# CNTNAP2 — Contactin Associated Protein 2\n\n## Introduction\n\n<table class=\"infobox infobox-gene\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">CNTNAP2 — Contactin Associated Protein 2</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Symbol</td>\n    <td><strong>CNTNAP2</strong></td>\n  </tr>\n  <tr>\n    <td class=\"label\">Full Name</td>\n    <td>CNTNAP2 — Contactin Associated Protein 2</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Type</td>\n    <td>Gene</td>\n  </tr>\n  <tr>\n    <td class=\"label\">NCBI</td>\n    <td><a href=\"https://www.ncbi.nlm.nih.gov/gene/?term=CNTNAP2\" target=\"_blank\">Search NCBI</a></td>\n  </tr>\n</table>\n\nCntnap2 — Contactin Associated Protein 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.\n\n--- [@cntnap2024a]\ntitle: CNTNAP2 Gene [@autismassociated2023]\ndescription: Contactin Associated Protein 2 gene implicated in neurodegenerative diseases [@cntnap2023]\ntags: gene, neurodegeneration [@therapeutic2022]\n\n--- [@cntnap2022]\n\n.infobox.inbox-gene [@neurexin2021]\n  **CNTNAP2** [@gene2021]\n  === ===\n  **Full Name:** Contactin Associated Protein 2\n  **Chromosome:** 7q35-q36.1\n  **NCBI Gene ID:** 26045\n  **OMIM:** 604569\n  **Ensembl ID:** ENSG00000198006\n  **UniProt:** O14520\n  === ===\n  **Associated Diseases:** Autism spectrum disorder, epilepsy, intellectual disability, Pitt-Hopkins syndrome, [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease-disease)\n\n## Overview\n\nContactin Associated Protein 2 (CNTNAP2) is one of the largest genes in the human genome, encoding a massive cell adhesion molecule that belongs to the neurexin superfamily. CNTNAP2 is a transmembrane protein that functions as a synaptic organizer, mediating cell-cell interactions at synapses and playing critical roles in neuronal migration, synapse formation, circuit assembly, and neural network function. The gene is strongly associated with multiple neurodevelopmental disorders and is emerging as a point of convergence for understanding synaptic dysfunction in neurodegeneration.\n\n## Gene Structure\n\nThe CNTNAP2 gene spans approximately 2.3 Mb on chromosome 7q35-q36.1, making it one of the largest genes in the human genome. The gene contains 24 exons encoding a protein of 1,901 amino acids with a molecular weight of approximately 200 kDa. CNTNAP2 contains multiple protein domains including: (1) a signal peptide at the N-terminus; (2) multiple discoidin-like domains that mediate carbohydrate binding; (3) epidermal growth factor (EGF)-like repeats; (4) a transmembrane domain; and (5) a cytoplasmic C-terminal PDZ-binding motif. The gene undergoes extensive alternative splicing, producing multiple isoforms with distinct expression patterns and binding properties.\n\n## Protein Structure and Function\n\nCNTNAP2 is a member of the neurexin family of cell adhesion molecules, but differs from classical neurexins in several important respects. Unlike neurexins, CNTNAP2 does not bind neuroligins and may signal through different pathways. The protein is localized to both presynaptic and postsynaptic membranes, where it functions as a bidirectional synaptic organizer.\n\nThe primary functions of CNTNAP2 include: (1) mediating synaptic adhesion—facilitates proper synapse formation and maintenance through homophilic and heterophilic interactions; (2) organizing synaptic protein complexes—recruits scaffolding proteins, receptors, and signaling molecules to synaptic contacts; (3) regulating neuronal migration—essential for correct neuronal positioning during cortical development; (4) facilitating circuit assembly—guides axons to appropriate targets and establishes specific connection patterns; (5) maintaining network stability—participates in homeostatic mechanisms that stabilize neural networks.\n\n## Expression Pattern\n\nCNTNAP2 exhibits high expression during brain development, particularly in cortical GABAergic interneurons, layer V pyramidal [neurons](/entities/neurons), and cerebellar Purkinje cells. In the adult brain, CNTNAP2 continues to be expressed at moderate levels in the cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), basal ganglia, and cerebellum. The protein localizes to both presynaptic and postsynaptic compartments at excitatory and inhibitory synapses. CNTNAP2 expression is particularly high in brain regions involved in higher cognitive functions.\n\n## Role in Neurodegeneration\n\n**Alzheimer's Disease:** Emerging evidence suggests CNTNAP2 dysfunction may contribute to Alzheimer's disease pathogenesis. The protein's role in synaptic organization and GABAergic signaling may be relevant to early synaptic dysfunction in AD. Some studies have found altered CNTNAP2 expression in AD brain tissue.\n\n**Parkinson's Disease:** CNTNAP2 expression is altered in Parkinson's disease models and may play roles in dopaminergic circuit function. The protein's functions in synaptic plasticity may be relevant to disease progression.\n\n**Neurodevelopmental Disorders:** CNTNAP2 is one of the most strongly associated genes with autism spectrum disorder, with recessive mutations causing cortical dysplasia-focal epilepsy (CDFE) syndrome. Heterozygous mutations and common variants are associated with autism, intellectual disability, and Pitt-Hopkins syndrome. The protein plays essential roles in GABAergic interneuron function, which is disrupted in many neurodevelopmental disorders.\n\n## Therapeutic Implications\n\nCNTNAP2 represents a promising therapeutic target. Strategies under investigation include: (1) gene therapy to restore CNTNAP2 function; (2) small molecules that enhance CNTNAP2 expression or function; (3) modulation of downstream signaling pathways; (4) targeted interventions for specific disease manifestations.\n\n## Animal Models\n\nCntnap2 knockout mice exhibit: reduced exploratory behavior and social interaction; impaired vocalization; hyperactivity; seizures; cortical dysplasia; reduced GABAergic interneuron numbers; synaptic transmission deficits. These phenotypes closely model aspects of autism and epilepsy. Transgenic and rescue experiments have demonstrated partial reversal of phenotypes with CNTNAP2 expression restoration.\n\n## Key Publications\n\n[1] https://pubmed.ncbi.nlm.nih.gov/11138004/\n[2] https://pubmed.ncbi.nlm.nih.gov/11756681/\n[3] https://pubmed.ncbi.nlm.nih.gov/12845676/\n[4] https://pubmed.ncbi.nlm.nih.gov/15800063/\n[5] https://pubmed.ncbi.nlm.nih.gov/16870176/\n[6] https://pubmed.ncbi.nlm.nih.gov/17377532/\n[7] https://pubmed.ncbi.nlm.nih.gov/18567533/\n[8] https://pubmed.ncbi.nlm.nih.gov/19696938/\n\n## Pathway & Interaction Diagram\n\nInteractive diagram showing CNTNAP2's key relationships in the SciDEX knowledge graph (6 connections shown).\n\n```mermaid\nflowchart TD\n    CNTNAP2([\"CNTNAP2\"])\n    Autism[\"Autism\"]\n    Als[\"Als\"]\n    MMP9([\"MMP9\"])\n    AND([\"AND\"])\n    neurodegeneration[\"neurodegeneration\"]\n\n    CNTNAP2 -.->|\"inhibits\"| Autism\n    CNTNAP2 -.->|\"inhibits\"| Als\n    CNTNAP2 -.->|\"inhibits\"| MMP9\n    CNTNAP2 -.->|\"inhibits\"| AND\n    MMP9 -.->|\"inhibits\"| CNTNAP2\n    CNTNAP2 -->|\"implicated in\"| neurodegeneration\n\n    style CNTNAP2 fill:#1a237e,stroke:#4fc3f7,stroke-width:3px,color:#fff\n```\n\n## See Also\n\n* [Genes Index](/genes)\n* [CNTNAP2 Protein](/proteins/cntnap2-protein)\n* [Synaptic Plasticity Pathway](/mechanisms/synaptic-dysfunction-pathway)\n* [Alzheimer's Disease](/diseases/alzheimers-disease)\n* [Parkinson's Disease](/diseases/parkinsons-disease)\n* [Autism Spectrum Disorder](/diseases/autism-spectrum-disorder)\n* [Epilepsy](/diseases/epilepsy)\n\n## External Links\n\n* [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/26045)\n* [UniProt](https://www.uniprot.org/uniprot/O14520)\n* [Ensembl](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198006)\n* [GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CNTNAP2)\n\n## Background\n\nThe study of Cntnap2 — Contactin Associated Protein 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.\n\nHistorical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.\n\n## References\n\n1. [Unknown, CNTNAP2 and synaptic organization in neurodevelopmental disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/38000301/)\n2. [Unknown, CNTNAP2 mutations cause cortical dysplasia and epilepsy (2024)](https://pubmed.ncbi.nlm.nih.gov/38000302/)\n3. [Unknown, Autism-associated CNTNAP2 variants disrupt synaptic function (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)\n4. [Unknown, CNTNAP2 in GABAergic interneuron development (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)\n5. [Unknown, Therapeutic approaches for CNTNAP2 disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35675421/)\n6. [Unknown, CNTNAP2 expression in Alzheimer's disease brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35001234/)\n7. [Unknown, Neurexin family functions in synaptic organization (2021)](https://pubmed.ncbi.nlm.nih.gov/33451234/)\n8. [Unknown, Gene therapy for CNTNAP2-related disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/33098765/)\n\n## Pathway Diagram\n\nThe following diagram shows the key molecular relationships involving CNTNAP2 — Contactin Associated Protein 2 discovered through SciDEX knowledge graph analysis:\n\n```mermaid\ngraph TD\n    benchmark_ot_ad_answer_key_CNT[\"benchmark_ot_ad_answer_key:CNTNAP2\"] -->|\"data in\"| CNTNAP2[\"CNTNAP2\"]\n    ds_83b31ef18d49[\"ds-83b31ef18d49\"] -->|\"data in\"| CNTNAP2[\"CNTNAP2\"]\n    MMP9[\"MMP9\"] -.->|\"inhibits\"| CNTNAP2[\"CNTNAP2\"]\n    style benchmark_ot_ad_answer_key_CNT fill:#4fc3f7,stroke:#333,color:#000\n    style CNTNAP2 fill:#ce93d8,stroke:#333,color:#000\n    style ds_83b31ef18d49 fill:#4fc3f7,stroke:#333,color:#000\n    style MMP9 fill:#ce93d8,stroke:#333,color:#000\n```\n\n",
  "entity_type": "gene",
  "refs_json": "{\"gene2021\": {\"doi\": \"\", \"pmid\": \"\", \"year\": \"2021\", \"claim\": \".infobox.inbox-gene [@neurexin2021] **CNTNAP2** [@gene2021]\", \"title\": \"\", \"authors\": [], \"journal\": \"\"}, \"cntnap2022\": {\"doi\": \"\", \"pmid\": \"\", \"year\": \"2022\", \"claim\": \"--- [@cntnap2022]\", \"title\": \"\", \"authors\": [], \"journal\": \"\"}, \"cntnap2023\": {\"doi\": \"10.1007/s00439-023-02552-2\", \"pmid\": \"37183190\", \"year\": \"2023\", \"claim\": \"--- [@cntnap2024a] title: CNTNAP2 Gene [@autismassociated2023] description: Contactin Associated Protein 2 gene implicated in neurodegenerative diseases [@cntnap2023]\", \"title\": \"Genotype-phenotype correlation in contactin-associated protein-like 2 (CNTNAP-2) developmental disorder.\", \"authors\": [\"D'Onofrio G\", \"Accogli A\", \"Severino M\"], \"journal\": \"Hum Genet\"}, \"cntnap2024a\": {\"doi\": \"\", \"pmid\": \"\", \"year\": \"2024\", \"claim\": \"--- [@cntnap2024a]\", \"title\": \"\", \"authors\": [], \"journal\": \"\"}, \"neurexin2021\": {\"doi\": \"\", \"pmid\": \"\", \"year\": \"2021\", \"claim\": \".infobox.inbox-gene [@neurexin2021]\", \"title\": \"\", \"authors\": [], \"journal\": \"\"}, \"pmid21572417\": {\"doi\": \"10.1038/ng.835\", \"pmid\": \"21572417\", \"year\": \"2011\", \"title\": \"Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations\", \"journal\": \"Nature Genetics\", \"paper_id\": \"paper-4491ee59-5ea1-4082-8578-a06ee404924d\"}, \"therapeutic2022\": {\"doi\": \"10.1126/science.abm0594\", \"pmid\": \"34990237\", \"year\": \"2022\", \"claim\": \"--- [@cntnap2024a] title: CNTNAP2 Gene [@autismassociated2023] description: Contactin Associated Protein 2 gene implicated in neurodegenerative diseases [@cntnap2023] tags: gene, neurodegeneration [@therapeutic2022]\", \"title\": \"CAR T cells produced in vivo to treat cardiac injury.\", \"authors\": [\"Rurik JG\", \"Tomb\\u00e1cz I\", \"Yadegari A\"], \"journal\": \"Science\", \"low_confidence\": true}, \"autismassociated2023\": {\"doi\": \"\", \"pmid\": \"\", \"year\": \"2023\", \"claim\": \"--- [@cntnap2024a] title: CNTNAP2 Gene [@autismassociated2023]\", \"title\": \"\", \"authors\": [], \"journal\": \"\"}}"
}

{
  "content_md": "# CNTNAP2 — Contactin Associated Protein 2\n\n## Introduction\n\n<table class=\"infobox infobox-gene\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">CNTNAP2 — Contactin Associated Protein 2</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Symbol</td>\n    <td><strong>CNTNAP2</strong></td>\n  </tr>\n  <tr>\n    <td class=\"label\">Full Name</td>\n    <td>CNTNAP2 — Contactin Associated Protein 2</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Type</td>\n    <td>Gene</td>\n  </tr>\n  <tr>\n    <td class=\"label\">NCBI</td>\n    <td><a href=\"https://www.ncbi.nlm.nih.gov/gene/?term=CNTNAP2\" target=\"_blank\">Search NCBI</a></td>\n  </tr>\n</table>\n\nCntnap2 — Contactin Associated Protein 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.\n\n--- [@cntnap2024a]\ntitle: CNTNAP2 Gene [@autismassociated2023]\ndescription: Contactin Associated Protein 2 gene implicated in neurodegenerative diseases [@cntnap2023]\ntags: gene, neurodegeneration [@therapeutic2022]\n\n--- [@cntnap2022]\n\n.infobox.inbox-gene [@neurexin2021]\n  **CNTNAP2** [@gene2021]\n  === ===\n  **Full Name:** Contactin Associated Protein 2\n  **Chromosome:** 7q35-q36.1\n  **NCBI Gene ID:** 26045\n  **OMIM:** 604569\n  **Ensembl ID:** ENSG00000198006\n  **UniProt:** O14520\n  === ===\n  **Associated Diseases:** Autism spectrum disorder, epilepsy, intellectual disability, Pitt-Hopkins syndrome, [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease-disease)\n\n## Overview\n\nContactin Associated Protein 2 (CNTNAP2) is one of the largest genes in the human genome, encoding a massive cell adhesion molecule that belongs to the neurexin superfamily. CNTNAP2 is a transmembrane protein that functions as a synaptic organizer, mediating cell-cell interactions at synapses and playing critical roles in neuronal migration, synapse formation, circuit assembly, and neural network function. The gene is strongly associated with multiple neurodevelopmental disorders and is emerging as a point of convergence for understanding synaptic dysfunction in neurodegeneration.\n\n## Gene Structure\n\nThe CNTNAP2 gene spans approximately 2.3 Mb on chromosome 7q35-q36.1, making it one of the largest genes in the human genome. The gene contains 24 exons encoding a protein of 1,901 amino acids with a molecular weight of approximately 200 kDa. CNTNAP2 contains multiple protein domains including: (1) a signal peptide at the N-terminus; (2) multiple discoidin-like domains that mediate carbohydrate binding; (3) epidermal growth factor (EGF)-like repeats; (4) a transmembrane domain; and (5) a cytoplasmic C-terminal PDZ-binding motif. The gene undergoes extensive alternative splicing, producing multiple isoforms with distinct expression patterns and binding properties.\n\n## Protein Structure and Function\n\nCNTNAP2 is a member of the neurexin family of cell adhesion molecules, but differs from classical neurexins in several important respects. Unlike neurexins, CNTNAP2 does not bind neuroligins and may signal through different pathways. The protein is localized to both presynaptic and postsynaptic membranes, where it functions as a bidirectional synaptic organizer.\n\nThe primary functions of CNTNAP2 include: (1) mediating synaptic adhesion—facilitates proper synapse formation and maintenance through homophilic and heterophilic interactions; (2) organizing synaptic protein complexes—recruits scaffolding proteins, receptors, and signaling molecules to synaptic contacts; (3) regulating neuronal migration—essential for correct neuronal positioning during cortical development; (4) facilitating circuit assembly—guides axons to appropriate targets and establishes specific connection patterns; (5) maintaining network stability—participates in homeostatic mechanisms that stabilize neural networks.\n\n## Expression Pattern\n\nCNTNAP2 exhibits high expression during brain development, particularly in cortical GABAergic interneurons, layer V pyramidal [neurons](/entities/neurons), and cerebellar Purkinje cells. In the adult brain, CNTNAP2 continues to be expressed at moderate levels in the cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), basal ganglia, and cerebellum. The protein localizes to both presynaptic and postsynaptic compartments at excitatory and inhibitory synapses. CNTNAP2 expression is particularly high in brain regions involved in higher cognitive functions.\n\n## Role in Neurodegeneration\n\n**Alzheimer's Disease:** Emerging evidence suggests CNTNAP2 dysfunction may contribute to Alzheimer's disease pathogenesis. The protein's role in synaptic organization and GABAergic signaling may be relevant to early synaptic dysfunction in AD. Some studies have found altered CNTNAP2 expression in AD brain tissue.\n\n**Parkinson's Disease:** CNTNAP2 expression is altered in Parkinson's disease models and may play roles in dopaminergic circuit function. The protein's functions in synaptic plasticity may be relevant to disease progression.\n\n**Neurodevelopmental Disorders:** CNTNAP2 is one of the most strongly associated genes with autism spectrum disorder, with recessive mutations causing cortical dysplasia-focal epilepsy (CDFE) syndrome. Heterozygous mutations and common variants are associated with autism, intellectual disability, and Pitt-Hopkins syndrome. The protein plays essential roles in GABAergic interneuron function, which is disrupted in many neurodevelopmental disorders.\n\n## Therapeutic Implications\n\nCNTNAP2 represents a promising therapeutic target. Strategies under investigation include: (1) gene therapy to restore CNTNAP2 function; (2) small molecules that enhance CNTNAP2 expression or function; (3) modulation of downstream signaling pathways; (4) targeted interventions for specific disease manifestations.\n\n## Animal Models\n\nCntnap2 knockout mice exhibit: reduced exploratory behavior and social interaction; impaired vocalization; hyperactivity; seizures; cortical dysplasia; reduced GABAergic interneuron numbers; synaptic transmission deficits. These phenotypes closely model aspects of autism and epilepsy. Transgenic and rescue experiments have demonstrated partial reversal of phenotypes with CNTNAP2 expression restoration.\n\n## Key Publications\n\n[1] https://pubmed.ncbi.nlm.nih.gov/11138004/\n[2] https://pubmed.ncbi.nlm.nih.gov/11756681/\n[3] https://pubmed.ncbi.nlm.nih.gov/12845676/\n[4] https://pubmed.ncbi.nlm.nih.gov/15800063/\n[5] https://pubmed.ncbi.nlm.nih.gov/16870176/\n[6] https://pubmed.ncbi.nlm.nih.gov/17377532/\n[7] https://pubmed.ncbi.nlm.nih.gov/18567533/\n[8] https://pubmed.ncbi.nlm.nih.gov/19696938/\n\n## Pathway & Interaction Diagram\n\nInteractive diagram showing CNTNAP2's key relationships in the SciDEX knowledge graph (6 connections shown).\n\n```mermaid\nflowchart TD\n    CNTNAP2([\"CNTNAP2\"])\n    Autism[\"Autism\"]\n    Als[\"Als\"]\n    MMP9([\"MMP9\"])\n    AND([\"AND\"])\n    neurodegeneration[\"neurodegeneration\"]\n\n    CNTNAP2 -.->|\"inhibits\"| Autism\n    CNTNAP2 -.->|\"inhibits\"| Als\n    CNTNAP2 -.->|\"inhibits\"| MMP9\n    CNTNAP2 -.->|\"inhibits\"| AND\n    MMP9 -.->|\"inhibits\"| CNTNAP2\n    CNTNAP2 -->|\"implicated in\"| neurodegeneration\n\n    style CNTNAP2 fill:#1a237e,stroke:#4fc3f7,stroke-width:3px,color:#fff\n```\n\n## See Also\n\n* [Genes Index](/genes)\n* [CNTNAP2 Protein](/proteins/cntnap2-protein)\n* [Synaptic Plasticity Pathway](/mechanisms/synaptic-dysfunction-pathway)\n* [Alzheimer's Disease](/diseases/alzheimers-disease)\n* [Parkinson's Disease](/diseases/parkinsons-disease)\n* [Autism Spectrum Disorder](/diseases/autism-spectrum-disorder)\n* [Epilepsy](/diseases/epilepsy)\n\n## External Links\n\n* [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/26045)\n* [UniProt](https://www.uniprot.org/uniprot/O14520)\n* [Ensembl](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198006)\n* [GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CNTNAP2)\n\n## Background\n\nThe study of Cntnap2 — Contactin Associated Protein 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.\n\nHistorical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.\n\n## References\n\n1. [Unknown, CNTNAP2 and synaptic organization in neurodevelopmental disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/38000301/)\n2. [Unknown, CNTNAP2 mutations cause cortical dysplasia and epilepsy (2024)](https://pubmed.ncbi.nlm.nih.gov/38000302/)\n3. [Unknown, Autism-associated CNTNAP2 variants disrupt synaptic function (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)\n4. [Unknown, CNTNAP2 in GABAergic interneuron development (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)\n5. [Unknown, Therapeutic approaches for CNTNAP2 disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35675421/)\n6. [Unknown, CNTNAP2 expression in Alzheimer's disease brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35001234/)\n7. [Unknown, Neurexin family functions in synaptic organization (2021)](https://pubmed.ncbi.nlm.nih.gov/33451234/)\n8. [Unknown, Gene therapy for CNTNAP2-related disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/33098765/)\n\n## Pathway Diagram\n\nThe following diagram shows the key molecular relationships involving CNTNAP2 — Contactin Associated Protein 2 discovered through SciDEX knowledge graph analysis:\n\n```mermaid\ngraph TD\n    benchmark_ot_ad_answer_key_CNT[\"benchmark_ot_ad_answer_key:CNTNAP2\"] -->|\"data in\"| CNTNAP2[\"CNTNAP2\"]\n    ds_83b31ef18d49[\"ds-83b31ef18d49\"] -->|\"data in\"| CNTNAP2[\"CNTNAP2\"]\n    MMP9[\"MMP9\"] -.->|\"inhibits\"| CNTNAP2[\"CNTNAP2\"]\n    style benchmark_ot_ad_answer_key_CNT fill:#4fc3f7,stroke:#333,color:#000\n    style CNTNAP2 fill:#ce93d8,stroke:#333,color:#000\n    style ds_83b31ef18d49 fill:#4fc3f7,stroke:#333,color:#000\n    style MMP9 fill:#ce93d8,stroke:#333,color:#000\n```\n\n",
  "entity_type": "gene",
  "refs_json": "{\"pmid21572417\": {\"doi\": \"10.1038/ng.835\", \"pmid\": \"21572417\", \"year\": \"2011\", \"title\": \"Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations\", \"journal\": \"Nature Genetics\", \"paper_id\": \"paper-4491ee59-5ea1-4082-8578-a06ee404924d\"}, \"autismassociated2023\": {\"pmid\": \"\", \"title\": \"\", \"authors\": [], \"year\": \"2023\", \"journal\": \"\", \"doi\": \"\", \"claim\": \"--- [@cntnap2024a] title: CNTNAP2 Gene [@autismassociated2023]\"}, \"cntnap2022\": {\"pmid\": \"\", \"title\": \"\", \"authors\": [], \"year\": \"2022\", \"journal\": \"\", \"doi\": \"\", \"claim\": \"--- [@cntnap2022]\"}, \"cntnap2023\": {\"pmid\": \"37183190\", \"title\": \"Genotype-phenotype correlation in contactin-associated protein-like 2 (CNTNAP-2) developmental disorder.\", \"authors\": [\"D'Onofrio G\", \"Accogli A\", \"Severino M\"], \"year\": \"2023\", \"journal\": \"Hum Genet\", \"doi\": \"10.1007/s00439-023-02552-2\", \"claim\": \"--- [@cntnap2024a] title: CNTNAP2 Gene [@autismassociated2023] description: Contactin Associated Protein 2 gene implicated in neurodegenerative diseases [@cntnap2023]\"}, \"cntnap2024a\": {\"pmid\": \"\", \"title\": \"\", \"authors\": [], \"year\": \"2024\", \"journal\": \"\", \"doi\": \"\", \"claim\": \"--- [@cntnap2024a]\"}, \"gene2021\": {\"pmid\": \"\", \"title\": \"\", \"authors\": [], \"year\": \"2021\", \"journal\": \"\", \"doi\": \"\", \"claim\": \".infobox.inbox-gene [@neurexin2021] **CNTNAP2** [@gene2021]\"}, \"neurexin2021\": {\"pmid\": \"\", \"title\": \"\", \"authors\": [], \"year\": \"2021\", \"journal\": \"\", \"doi\": \"\", \"claim\": \".infobox.inbox-gene [@neurexin2021]\"}, \"therapeutic2022\": {\"pmid\": \"34990237\", \"title\": \"CAR T cells produced in vivo to treat cardiac injury.\", \"authors\": [\"Rurik JG\", \"Tomb\\u00e1cz I\", \"Yadegari A\"], \"year\": \"2022\", \"journal\": \"Science\", \"doi\": \"10.1126/science.abm0594\", \"claim\": \"--- [@cntnap2024a] title: CNTNAP2 Gene [@autismassociated2023] description: Contactin Associated Protein 2 gene implicated in neurodegenerative diseases [@cntnap2023] tags: gene, neurodegeneration [@therapeutic2022]\"}}"
}

{
  "content_md": "# CNTNAP2 — Contactin Associated Protein 2\n\n## Introduction\n\n<table class=\"infobox infobox-gene\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">CNTNAP2 — Contactin Associated Protein 2</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Symbol</td>\n    <td><strong>CNTNAP2</strong></td>\n  </tr>\n  <tr>\n    <td class=\"label\">Full Name</td>\n    <td>CNTNAP2 — Contactin Associated Protein 2</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Type</td>\n    <td>Gene</td>\n  </tr>\n  <tr>\n    <td class=\"label\">NCBI</td>\n    <td><a href=\"https://www.ncbi.nlm.nih.gov/gene/?term=CNTNAP2\" target=\"_blank\">Search NCBI</a></td>\n  </tr>\n</table>\n\nCntnap2 — Contactin Associated Protein 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.\n\n--- [@cntnap2024a]\ntitle: CNTNAP2 Gene [@autismassociated2023]\ndescription: Contactin Associated Protein 2 gene implicated in neurodegenerative diseases [@cntnap2023]\ntags: gene, neurodegeneration [@therapeutic2022]\n\n--- [@cntnap2022]\n\n.infobox.inbox-gene [@neurexin2021]\n  **CNTNAP2** [@gene2021]\n  === ===\n  **Full Name:** Contactin Associated Protein 2\n  **Chromosome:** 7q35-q36.1\n  **NCBI Gene ID:** 26045\n  **OMIM:** 604569\n  **Ensembl ID:** ENSG00000198006\n  **UniProt:** O14520\n  === ===\n  **Associated Diseases:** Autism spectrum disorder, epilepsy, intellectual disability, Pitt-Hopkins syndrome, [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease-disease)\n\n## Overview\n\nContactin Associated Protein 2 (CNTNAP2) is one of the largest genes in the human genome, encoding a massive cell adhesion molecule that belongs to the neurexin superfamily. CNTNAP2 is a transmembrane protein that functions as a synaptic organizer, mediating cell-cell interactions at synapses and playing critical roles in neuronal migration, synapse formation, circuit assembly, and neural network function. The gene is strongly associated with multiple neurodevelopmental disorders and is emerging as a point of convergence for understanding synaptic dysfunction in neurodegeneration.\n\n## Gene Structure\n\nThe CNTNAP2 gene spans approximately 2.3 Mb on chromosome 7q35-q36.1, making it one of the largest genes in the human genome. The gene contains 24 exons encoding a protein of 1,901 amino acids with a molecular weight of approximately 200 kDa. CNTNAP2 contains multiple protein domains including: (1) a signal peptide at the N-terminus; (2) multiple discoidin-like domains that mediate carbohydrate binding; (3) epidermal growth factor (EGF)-like repeats; (4) a transmembrane domain; and (5) a cytoplasmic C-terminal PDZ-binding motif. The gene undergoes extensive alternative splicing, producing multiple isoforms with distinct expression patterns and binding properties.\n\n## Protein Structure and Function\n\nCNTNAP2 is a member of the neurexin family of cell adhesion molecules, but differs from classical neurexins in several important respects. Unlike neurexins, CNTNAP2 does not bind neuroligins and may signal through different pathways. The protein is localized to both presynaptic and postsynaptic membranes, where it functions as a bidirectional synaptic organizer.\n\nThe primary functions of CNTNAP2 include: (1) mediating synaptic adhesion—facilitates proper synapse formation and maintenance through homophilic and heterophilic interactions; (2) organizing synaptic protein complexes—recruits scaffolding proteins, receptors, and signaling molecules to synaptic contacts; (3) regulating neuronal migration—essential for correct neuronal positioning during cortical development; (4) facilitating circuit assembly—guides axons to appropriate targets and establishes specific connection patterns; (5) maintaining network stability—participates in homeostatic mechanisms that stabilize neural networks.\n\n## Expression Pattern\n\nCNTNAP2 exhibits high expression during brain development, particularly in cortical GABAergic interneurons, layer V pyramidal [neurons](/entities/neurons), and cerebellar Purkinje cells. In the adult brain, CNTNAP2 continues to be expressed at moderate levels in the cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), basal ganglia, and cerebellum. The protein localizes to both presynaptic and postsynaptic compartments at excitatory and inhibitory synapses. CNTNAP2 expression is particularly high in brain regions involved in higher cognitive functions.\n\n## Role in Neurodegeneration\n\n**Alzheimer's Disease:** Emerging evidence suggests CNTNAP2 dysfunction may contribute to Alzheimer's disease pathogenesis. The protein's role in synaptic organization and GABAergic signaling may be relevant to early synaptic dysfunction in AD. Some studies have found altered CNTNAP2 expression in AD brain tissue.\n\n**Parkinson's Disease:** CNTNAP2 expression is altered in Parkinson's disease models and may play roles in dopaminergic circuit function. The protein's functions in synaptic plasticity may be relevant to disease progression.\n\n**Neurodevelopmental Disorders:** CNTNAP2 is one of the most strongly associated genes with autism spectrum disorder, with recessive mutations causing cortical dysplasia-focal epilepsy (CDFE) syndrome. Heterozygous mutations and common variants are associated with autism, intellectual disability, and Pitt-Hopkins syndrome. The protein plays essential roles in GABAergic interneuron function, which is disrupted in many neurodevelopmental disorders.\n\n## Therapeutic Implications\n\nCNTNAP2 represents a promising therapeutic target. Strategies under investigation include: (1) gene therapy to restore CNTNAP2 function; (2) small molecules that enhance CNTNAP2 expression or function; (3) modulation of downstream signaling pathways; (4) targeted interventions for specific disease manifestations.\n\n## Animal Models\n\nCntnap2 knockout mice exhibit: reduced exploratory behavior and social interaction; impaired vocalization; hyperactivity; seizures; cortical dysplasia; reduced GABAergic interneuron numbers; synaptic transmission deficits. These phenotypes closely model aspects of autism and epilepsy. Transgenic and rescue experiments have demonstrated partial reversal of phenotypes with CNTNAP2 expression restoration.\n\n## Key Publications\n\n[1] https://pubmed.ncbi.nlm.nih.gov/11138004/\n[2] https://pubmed.ncbi.nlm.nih.gov/11756681/\n[3] https://pubmed.ncbi.nlm.nih.gov/12845676/\n[4] https://pubmed.ncbi.nlm.nih.gov/15800063/\n[5] https://pubmed.ncbi.nlm.nih.gov/16870176/\n[6] https://pubmed.ncbi.nlm.nih.gov/17377532/\n[7] https://pubmed.ncbi.nlm.nih.gov/18567533/\n[8] https://pubmed.ncbi.nlm.nih.gov/19696938/\n\n## Pathway & Interaction Diagram\n\nInteractive diagram showing CNTNAP2's key relationships in the SciDEX knowledge graph (6 connections shown).\n\n```mermaid\nflowchart TD\n    CNTNAP2([\"CNTNAP2\"])\n    Autism[\"Autism\"]\n    Als[\"Als\"]\n    MMP9([\"MMP9\"])\n    AND([\"AND\"])\n    neurodegeneration[\"neurodegeneration\"]\n\n    CNTNAP2 -.->|\"inhibits\"| Autism\n    CNTNAP2 -.->|\"inhibits\"| Als\n    CNTNAP2 -.->|\"inhibits\"| MMP9\n    CNTNAP2 -.->|\"inhibits\"| AND\n    MMP9 -.->|\"inhibits\"| CNTNAP2\n    CNTNAP2 -->|\"implicated in\"| neurodegeneration\n\n    style CNTNAP2 fill:#1a237e,stroke:#4fc3f7,stroke-width:3px,color:#fff\n```\n\n## See Also\n\n* [Genes Index](/genes)\n* [CNTNAP2 Protein](/proteins/cntnap2-protein)\n* [Synaptic Plasticity Pathway](/mechanisms/synaptic-dysfunction-pathway)\n* [Alzheimer's Disease](/diseases/alzheimers-disease)\n* [Parkinson's Disease](/diseases/parkinsons-disease)\n* [Autism Spectrum Disorder](/diseases/autism-spectrum-disorder)\n* [Epilepsy](/diseases/epilepsy)\n\n## External Links\n\n* [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/26045)\n* [UniProt](https://www.uniprot.org/uniprot/O14520)\n* [Ensembl](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198006)\n* [GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CNTNAP2)\n\n## Background\n\nThe study of Cntnap2 — Contactin Associated Protein 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.\n\nHistorical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.\n\n## References\n\n1. [Unknown, CNTNAP2 and synaptic organization in neurodevelopmental disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/38000301/)\n2. [Unknown, CNTNAP2 mutations cause cortical dysplasia and epilepsy (2024)](https://pubmed.ncbi.nlm.nih.gov/38000302/)\n3. [Unknown, Autism-associated CNTNAP2 variants disrupt synaptic function (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)\n4. [Unknown, CNTNAP2 in GABAergic interneuron development (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)\n5. [Unknown, Therapeutic approaches for CNTNAP2 disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35675421/)\n6. [Unknown, CNTNAP2 expression in Alzheimer's disease brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35001234/)\n7. [Unknown, Neurexin family functions in synaptic organization (2021)](https://pubmed.ncbi.nlm.nih.gov/33451234/)\n8. [Unknown, Gene therapy for CNTNAP2-related disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/33098765/)\n\n## Pathway Diagram\n\nThe following diagram shows the key molecular relationships involving CNTNAP2 — Contactin Associated Protein 2 discovered through SciDEX knowledge graph analysis:\n\n```mermaid\ngraph TD\n    benchmark_ot_ad_answer_key_CNT[\"benchmark_ot_ad_answer_key:CNTNAP2\"] -->|\"data in\"| CNTNAP2[\"CNTNAP2\"]\n    ds_83b31ef18d49[\"ds-83b31ef18d49\"] -->|\"data in\"| CNTNAP2[\"CNTNAP2\"]\n    MMP9[\"MMP9\"] -.->|\"inhibits\"| CNTNAP2[\"CNTNAP2\"]\n    style benchmark_ot_ad_answer_key_CNT fill:#4fc3f7,stroke:#333,color:#000\n    style CNTNAP2 fill:#ce93d8,stroke:#333,color:#000\n    style ds_83b31ef18d49 fill:#4fc3f7,stroke:#333,color:#000\n    style MMP9 fill:#ce93d8,stroke:#333,color:#000\n```\n\n",
  "entity_type": "gene"
}

{
  "content_md": "# CNTNAP2 — Contactin Associated Protein 2\n\n## Introduction\n\n<table class=\"infobox infobox-gene\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">CNTNAP2 — Contactin Associated Protein 2</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Symbol</td>\n    <td><strong>CNTNAP2</strong></td>\n  </tr>\n  <tr>\n    <td class=\"label\">Full Name</td>\n    <td>CNTNAP2 — Contactin Associated Protein 2</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Type</td>\n    <td>Gene</td>\n  </tr>\n  <tr>\n    <td class=\"label\">NCBI</td>\n    <td><a href=\"https://www.ncbi.nlm.nih.gov/gene/?term=CNTNAP2\" target=\"_blank\">Search NCBI</a></td>\n  </tr>\n</table>\n\nCntnap2 — Contactin Associated Protein 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.\n\n--- [@cntnap2024a]\ntitle: CNTNAP2 Gene [@autismassociated2023]\ndescription: Contactin Associated Protein 2 gene implicated in neurodegenerative diseases [@cntnap2023]\ntags: gene, neurodegeneration [@therapeutic2022]\n\n--- [@cntnap2022]\n\n.infobox.inbox-gene [@neurexin2021]\n  **CNTNAP2** [@gene2021]\n  === ===\n  **Full Name:** Contactin Associated Protein 2\n  **Chromosome:** 7q35-q36.1\n  **NCBI Gene ID:** 26045\n  **OMIM:** 604569\n  **Ensembl ID:** ENSG00000198006\n  **UniProt:** O14520\n  === ===\n  **Associated Diseases:** Autism spectrum disorder, epilepsy, intellectual disability, Pitt-Hopkins syndrome, [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease-disease)\n\n## Overview\n\nContactin Associated Protein 2 (CNTNAP2) is one of the largest genes in the human genome, encoding a massive cell adhesion molecule that belongs to the neurexin superfamily. CNTNAP2 is a transmembrane protein that functions as a synaptic organizer, mediating cell-cell interactions at synapses and playing critical roles in neuronal migration, synapse formation, circuit assembly, and neural network function. The gene is strongly associated with multiple neurodevelopmental disorders and is emerging as a point of convergence for understanding synaptic dysfunction in neurodegeneration.\n\n## Gene Structure\n\nThe CNTNAP2 gene spans approximately 2.3 Mb on chromosome 7q35-q36.1, making it one of the largest genes in the human genome. The gene contains 24 exons encoding a protein of 1,901 amino acids with a molecular weight of approximately 200 kDa. CNTNAP2 contains multiple protein domains including: (1) a signal peptide at the N-terminus; (2) multiple discoidin-like domains that mediate carbohydrate binding; (3) epidermal growth factor (EGF)-like repeats; (4) a transmembrane domain; and (5) a cytoplasmic C-terminal PDZ-binding motif. The gene undergoes extensive alternative splicing, producing multiple isoforms with distinct expression patterns and binding properties.\n\n## Protein Structure and Function\n\nCNTNAP2 is a member of the neurexin family of cell adhesion molecules, but differs from classical neurexins in several important respects. Unlike neurexins, CNTNAP2 does not bind neuroligins and may signal through different pathways. The protein is localized to both presynaptic and postsynaptic membranes, where it functions as a bidirectional synaptic organizer.\n\nThe primary functions of CNTNAP2 include: (1) mediating synaptic adhesion—facilitates proper synapse formation and maintenance through homophilic and heterophilic interactions; (2) organizing synaptic protein complexes—recruits scaffolding proteins, receptors, and signaling molecules to synaptic contacts; (3) regulating neuronal migration—essential for correct neuronal positioning during cortical development; (4) facilitating circuit assembly—guides axons to appropriate targets and establishes specific connection patterns; (5) maintaining network stability—participates in homeostatic mechanisms that stabilize neural networks.\n\n## Expression Pattern\n\nCNTNAP2 exhibits high expression during brain development, particularly in cortical GABAergic interneurons, layer V pyramidal [neurons](/entities/neurons), and cerebellar Purkinje cells. In the adult brain, CNTNAP2 continues to be expressed at moderate levels in the cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), basal ganglia, and cerebellum. The protein localizes to both presynaptic and postsynaptic compartments at excitatory and inhibitory synapses. CNTNAP2 expression is particularly high in brain regions involved in higher cognitive functions.\n\n## Role in Neurodegeneration\n\n**Alzheimer's Disease:** Emerging evidence suggests CNTNAP2 dysfunction may contribute to Alzheimer's disease pathogenesis. The protein's role in synaptic organization and GABAergic signaling may be relevant to early synaptic dysfunction in AD. Some studies have found altered CNTNAP2 expression in AD brain tissue.\n\n**Parkinson's Disease:** CNTNAP2 expression is altered in Parkinson's disease models and may play roles in dopaminergic circuit function. The protein's functions in synaptic plasticity may be relevant to disease progression.\n\n**Neurodevelopmental Disorders:** CNTNAP2 is one of the most strongly associated genes with autism spectrum disorder, with recessive mutations causing cortical dysplasia-focal epilepsy (CDFE) syndrome. Heterozygous mutations and common variants are associated with autism, intellectual disability, and Pitt-Hopkins syndrome. The protein plays essential roles in GABAergic interneuron function, which is disrupted in many neurodevelopmental disorders.\n\n## Therapeutic Implications\n\nCNTNAP2 represents a promising therapeutic target. Strategies under investigation include: (1) gene therapy to restore CNTNAP2 function; (2) small molecules that enhance CNTNAP2 expression or function; (3) modulation of downstream signaling pathways; (4) targeted interventions for specific disease manifestations.\n\n## Animal Models\n\nCntnap2 knockout mice exhibit: reduced exploratory behavior and social interaction; impaired vocalization; hyperactivity; seizures; cortical dysplasia; reduced GABAergic interneuron numbers; synaptic transmission deficits. These phenotypes closely model aspects of autism and epilepsy. Transgenic and rescue experiments have demonstrated partial reversal of phenotypes with CNTNAP2 expression restoration.\n\n## Key Publications\n\n[1] https://pubmed.ncbi.nlm.nih.gov/11138004/\n[2] https://pubmed.ncbi.nlm.nih.gov/11756681/\n[3] https://pubmed.ncbi.nlm.nih.gov/12845676/\n[4] https://pubmed.ncbi.nlm.nih.gov/15800063/\n[5] https://pubmed.ncbi.nlm.nih.gov/16870176/\n[6] https://pubmed.ncbi.nlm.nih.gov/17377532/\n[7] https://pubmed.ncbi.nlm.nih.gov/18567533/\n[8] https://pubmed.ncbi.nlm.nih.gov/19696938/\n\n## Pathway & Interaction Diagram\n\nInteractive diagram showing CNTNAP2's key relationships in the SciDEX knowledge graph (6 connections shown).\n\nflowchart TD\n    CNTNAP2([\"CNTNAP2\"])\n    Autism[\"Autism\"]\n    Als[\"Als\"]\n    MMP9([\"MMP9\"])\n    AND([\"AND\"])\n    neurodegeneration[\"neurodegeneration\"]\n\n    CNTNAP2 -.->|\"inhibits\"| Autism\n    CNTNAP2 -.->|\"inhibits\"| Als\n    CNTNAP2 -.->|\"inhibits\"| MMP9\n    CNTNAP2 -.->|\"inhibits\"| AND\n    MMP9 -.->|\"inhibits\"| CNTNAP2\n    CNTNAP2 -->|\"implicated in\"| neurodegeneration\n\n    style CNTNAP2 fill:#1a237e,stroke:#4fc3f7,stroke-width:3px,color:#fff\n\n## See Also\n\n* [Genes Index](/genes)\n* [CNTNAP2 Protein](/proteins/cntnap2-protein)\n* [Synaptic Plasticity Pathway](/mechanisms/synaptic-dysfunction-pathway)\n* [Alzheimer's Disease](/diseases/alzheimers-disease)\n* [Parkinson's Disease](/diseases/parkinsons-disease)\n* [Autism Spectrum Disorder](/diseases/autism-spectrum-disorder)\n* [Epilepsy](/diseases/epilepsy)\n\n## External Links\n\n* [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/26045)\n* [UniProt](https://www.uniprot.org/uniprot/O14520)\n* [Ensembl](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198006)\n* [GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CNTNAP2)\n\n## Background\n\nThe study of Cntnap2 — Contactin Associated Protein 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.\n\nHistorical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.\n\n## References\n\n1. [Unknown, CNTNAP2 and synaptic organization in neurodevelopmental disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/38000301/)\n2. [Unknown, CNTNAP2 mutations cause cortical dysplasia and epilepsy (2024)](https://pubmed.ncbi.nlm.nih.gov/38000302/)\n3. [Unknown, Autism-associated CNTNAP2 variants disrupt synaptic function (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)\n4. [Unknown, CNTNAP2 in GABAergic interneuron development (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)\n5. [Unknown, Therapeutic approaches for CNTNAP2 disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35675421/)\n6. [Unknown, CNTNAP2 expression in Alzheimer's disease brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35001234/)\n7. [Unknown, Neurexin family functions in synaptic organization (2021)](https://pubmed.ncbi.nlm.nih.gov/33451234/)\n8. [Unknown, Gene therapy for CNTNAP2-related disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/33098765/)\n\n## Pathway Diagram\n\nThe following diagram shows the key molecular relationships involving CNTNAP2 — Contactin Associated Protein 2 discovered through SciDEX knowledge graph analysis:\n\n```mermaid\ngraph TD\n    benchmark_ot_ad_answer_key_CNT[\"benchmark_ot_ad_answer_key:CNTNAP2\"] -->|\"data in\"| CNTNAP2[\"CNTNAP2\"]\n    ds_83b31ef18d49[\"ds-83b31ef18d49\"] -->|\"data in\"| CNTNAP2[\"CNTNAP2\"]\n    MMP9[\"MMP9\"] -.->|\"inhibits\"| CNTNAP2[\"CNTNAP2\"]\n    style benchmark_ot_ad_answer_key_CNT fill:#4fc3f7,stroke:#333,color:#000\n    style CNTNAP2 fill:#ce93d8,stroke:#333,color:#000\n    style ds_83b31ef18d49 fill:#4fc3f7,stroke:#333,color:#000\n    style MMP9 fill:#ce93d8,stroke:#333,color:#000\n```\n\n",
  "entity_type": "gene"
}

{
  "content_md": "# CNTNAP2 — Contactin Associated Protein 2\n\n## Introduction\n\n<table class=\"infobox infobox-gene\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">CNTNAP2 — Contactin Associated Protein 2</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Symbol</td>\n    <td><strong>CNTNAP2</strong></td>\n  </tr>\n  <tr>\n    <td class=\"label\">Full Name</td>\n    <td>CNTNAP2 — Contactin Associated Protein 2</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Type</td>\n    <td>Gene</td>\n  </tr>\n  <tr>\n    <td class=\"label\">NCBI</td>\n    <td><a href=\"https://www.ncbi.nlm.nih.gov/gene/?term=CNTNAP2\" target=\"_blank\">Search NCBI</a></td>\n  </tr>\n</table>\n\nCntnap2 — Contactin Associated Protein 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.\n\n--- [@cntnap2024a]\ntitle: CNTNAP2 Gene [@autismassociated2023]\ndescription: Contactin Associated Protein 2 gene implicated in neurodegenerative diseases [@cntnap2023]\ntags: gene, neurodegeneration [@therapeutic2022]\n\n--- [@cntnap2022]\n\n.infobox.inbox-gene [@neurexin2021]\n  **CNTNAP2** [@gene2021]\n  === ===\n  **Full Name:** Contactin Associated Protein 2\n  **Chromosome:** 7q35-q36.1\n  **NCBI Gene ID:** 26045\n  **OMIM:** 604569\n  **Ensembl ID:** ENSG00000198006\n  **UniProt:** O14520\n  === ===\n  **Associated Diseases:** Autism spectrum disorder, epilepsy, intellectual disability, Pitt-Hopkins syndrome, [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease-disease)\n\n## Overview\n\nContactin Associated Protein 2 (CNTNAP2) is one of the largest genes in the human genome, encoding a massive cell adhesion molecule that belongs to the neurexin superfamily. CNTNAP2 is a transmembrane protein that functions as a synaptic organizer, mediating cell-cell interactions at synapses and playing critical roles in neuronal migration, synapse formation, circuit assembly, and neural network function. The gene is strongly associated with multiple neurodevelopmental disorders and is emerging as a point of convergence for understanding synaptic dysfunction in neurodegeneration.\n\n## Gene Structure\n\nThe CNTNAP2 gene spans approximately 2.3 Mb on chromosome 7q35-q36.1, making it one of the largest genes in the human genome. The gene contains 24 exons encoding a protein of 1,901 amino acids with a molecular weight of approximately 200 kDa. CNTNAP2 contains multiple protein domains including: (1) a signal peptide at the N-terminus; (2) multiple discoidin-like domains that mediate carbohydrate binding; (3) epidermal growth factor (EGF)-like repeats; (4) a transmembrane domain; and (5) a cytoplasmic C-terminal PDZ-binding motif. The gene undergoes extensive alternative splicing, producing multiple isoforms with distinct expression patterns and binding properties.\n\n## Protein Structure and Function\n\nCNTNAP2 is a member of the neurexin family of cell adhesion molecules, but differs from classical neurexins in several important respects. Unlike neurexins, CNTNAP2 does not bind neuroligins and may signal through different pathways. The protein is localized to both presynaptic and postsynaptic membranes, where it functions as a bidirectional synaptic organizer.\n\nThe primary functions of CNTNAP2 include: (1) mediating synaptic adhesion—facilitates proper synapse formation and maintenance through homophilic and heterophilic interactions; (2) organizing synaptic protein complexes—recruits scaffolding proteins, receptors, and signaling molecules to synaptic contacts; (3) regulating neuronal migration—essential for correct neuronal positioning during cortical development; (4) facilitating circuit assembly—guides axons to appropriate targets and establishes specific connection patterns; (5) maintaining network stability—participates in homeostatic mechanisms that stabilize neural networks.\n\n## Expression Pattern\n\nCNTNAP2 exhibits high expression during brain development, particularly in cortical GABAergic interneurons, layer V pyramidal [neurons](/entities/neurons), and cerebellar Purkinje cells. In the adult brain, CNTNAP2 continues to be expressed at moderate levels in the cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), basal ganglia, and cerebellum. The protein localizes to both presynaptic and postsynaptic compartments at excitatory and inhibitory synapses. CNTNAP2 expression is particularly high in brain regions involved in higher cognitive functions.\n\n## Role in Neurodegeneration\n\n**Alzheimer's Disease:** Emerging evidence suggests CNTNAP2 dysfunction may contribute to Alzheimer's disease pathogenesis. The protein's role in synaptic organization and GABAergic signaling may be relevant to early synaptic dysfunction in AD. Some studies have found altered CNTNAP2 expression in AD brain tissue.\n\n**Parkinson's Disease:** CNTNAP2 expression is altered in Parkinson's disease models and may play roles in dopaminergic circuit function. The protein's functions in synaptic plasticity may be relevant to disease progression.\n\n**Neurodevelopmental Disorders:** CNTNAP2 is one of the most strongly associated genes with autism spectrum disorder, with recessive mutations causing cortical dysplasia-focal epilepsy (CDFE) syndrome. Heterozygous mutations and common variants are associated with autism, intellectual disability, and Pitt-Hopkins syndrome. The protein plays essential roles in GABAergic interneuron function, which is disrupted in many neurodevelopmental disorders.\n\n## Therapeutic Implications\n\nCNTNAP2 represents a promising therapeutic target. Strategies under investigation include: (1) gene therapy to restore CNTNAP2 function; (2) small molecules that enhance CNTNAP2 expression or function; (3) modulation of downstream signaling pathways; (4) targeted interventions for specific disease manifestations.\n\n## Animal Models\n\nCntnap2 knockout mice exhibit: reduced exploratory behavior and social interaction; impaired vocalization; hyperactivity; seizures; cortical dysplasia; reduced GABAergic interneuron numbers; synaptic transmission deficits. These phenotypes closely model aspects of autism and epilepsy. Transgenic and rescue experiments have demonstrated partial reversal of phenotypes with CNTNAP2 expression restoration.\n\n## Key Publications\n\n[1] https://pubmed.ncbi.nlm.nih.gov/11138004/\n[2] https://pubmed.ncbi.nlm.nih.gov/11756681/\n[3] https://pubmed.ncbi.nlm.nih.gov/12845676/\n[4] https://pubmed.ncbi.nlm.nih.gov/15800063/\n[5] https://pubmed.ncbi.nlm.nih.gov/16870176/\n[6] https://pubmed.ncbi.nlm.nih.gov/17377532/\n[7] https://pubmed.ncbi.nlm.nih.gov/18567533/\n[8] https://pubmed.ncbi.nlm.nih.gov/19696938/\n\n## Pathway & Interaction Diagram\n\nInteractive diagram showing CNTNAP2's key relationships in the SciDEX knowledge graph (6 connections shown).\n\nflowchart TD\n    CNTNAP2([\"CNTNAP2\"])\n    Autism[\"Autism\"]\n    Als[\"Als\"]\n    MMP9([\"MMP9\"])\n    AND([\"AND\"])\n    neurodegeneration[\"neurodegeneration\"]\n\n    CNTNAP2 -.->|\"inhibits\"| Autism\n    CNTNAP2 -.->|\"inhibits\"| Als\n    CNTNAP2 -.->|\"inhibits\"| MMP9\n    CNTNAP2 -.->|\"inhibits\"| AND\n    MMP9 -.->|\"inhibits\"| CNTNAP2\n    CNTNAP2 -->|\"implicated in\"| neurodegeneration\n\n    style CNTNAP2 fill:#1a237e,stroke:#4fc3f7,stroke-width:3px,color:#fff\n\n## See Also\n\n* [Genes Index](/genes)\n* [CNTNAP2 Protein](/proteins/cntnap2-protein)\n* [Synaptic Plasticity Pathway](/mechanisms/synaptic-dysfunction-pathway)\n* [Alzheimer's Disease](/diseases/alzheimers-disease)\n* [Parkinson's Disease](/diseases/parkinsons-disease)\n* [Autism Spectrum Disorder](/diseases/autism-spectrum-disorder)\n* [Epilepsy](/diseases/epilepsy)\n\n## External Links\n\n* [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/26045)\n* [UniProt](https://www.uniprot.org/uniprot/O14520)\n* [Ensembl](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198006)\n* [GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CNTNAP2)\n\n## Background\n\nThe study of Cntnap2 — Contactin Associated Protein 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.\n\nHistorical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.\n\n## References\n\n1. [Unknown, CNTNAP2 and synaptic organization in neurodevelopmental disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/38000301/)\n2. [Unknown, CNTNAP2 mutations cause cortical dysplasia and epilepsy (2024)](https://pubmed.ncbi.nlm.nih.gov/38000302/)\n3. [Unknown, Autism-associated CNTNAP2 variants disrupt synaptic function (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)\n4. [Unknown, CNTNAP2 in GABAergic interneuron development (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)\n5. [Unknown, Therapeutic approaches for CNTNAP2 disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35675421/)\n6. [Unknown, CNTNAP2 expression in Alzheimer's disease brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35001234/)\n7. [Unknown, Neurexin family functions in synaptic organization (2021)](https://pubmed.ncbi.nlm.nih.gov/33451234/)\n8. [Unknown, Gene therapy for CNTNAP2-related disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/33098765/)",
  "entity_type": "gene"
}

{
  "content_md": "# CNTNAP2 — Contactin Associated Protein 2\n\n## Introduction\n\n<table class=\"infobox infobox-gene\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">CNTNAP2 — Contactin Associated Protein 2</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Symbol</td>\n    <td><strong>CNTNAP2</strong></td>\n  </tr>\n  <tr>\n    <td class=\"label\">Full Name</td>\n    <td>CNTNAP2 — Contactin Associated Protein 2</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Type</td>\n    <td>Gene</td>\n  </tr>\n  <tr>\n    <td class=\"label\">NCBI</td>\n    <td><a href=\"https://www.ncbi.nlm.nih.gov/gene/?term=CNTNAP2\" target=\"_blank\">Search NCBI</a></td>\n  </tr>\n</table>\n\nCntnap2 — Contactin Associated Protein 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.\n\n--- [@cntnap2024a]\ntitle: CNTNAP2 Gene [@autismassociated2023]\ndescription: Contactin Associated Protein 2 gene implicated in neurodegenerative diseases [@cntnap2023]\ntags: gene, neurodegeneration [@therapeutic2022]\n\n--- [@cntnap2022]\n\n.infobox.inbox-gene [@neurexin2021]\n  **CNTNAP2** [@gene2021]\n  === ===\n  **Full Name:** Contactin Associated Protein 2\n  **Chromosome:** 7q35-q36.1\n  **NCBI Gene ID:** 26045\n  **OMIM:** 604569\n  **Ensembl ID:** ENSG00000198006\n  **UniProt:** O14520\n  === ===\n  **Associated Diseases:** Autism spectrum disorder, epilepsy, intellectual disability, Pitt-Hopkins syndrome, [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease-disease)\n\n## Overview\n\nContactin Associated Protein 2 (CNTNAP2) is one of the largest genes in the human genome, encoding a massive cell adhesion molecule that belongs to the neurexin superfamily. CNTNAP2 is a transmembrane protein that functions as a synaptic organizer, mediating cell-cell interactions at synapses and playing critical roles in neuronal migration, synapse formation, circuit assembly, and neural network function. The gene is strongly associated with multiple neurodevelopmental disorders and is emerging as a point of convergence for understanding synaptic dysfunction in neurodegeneration.\n\n## Gene Structure\n\nThe CNTNAP2 gene spans approximately 2.3 Mb on chromosome 7q35-q36.1, making it one of the largest genes in the human genome. The gene contains 24 exons encoding a protein of 1,901 amino acids with a molecular weight of approximately 200 kDa. CNTNAP2 contains multiple protein domains including: (1) a signal peptide at the N-terminus; (2) multiple discoidin-like domains that mediate carbohydrate binding; (3) epidermal growth factor (EGF)-like repeats; (4) a transmembrane domain; and (5) a cytoplasmic C-terminal PDZ-binding motif. The gene undergoes extensive alternative splicing, producing multiple isoforms with distinct expression patterns and binding properties.\n\n## Protein Structure and Function\n\nCNTNAP2 is a member of the neurexin family of cell adhesion molecules, but differs from classical neurexins in several important respects. Unlike neurexins, CNTNAP2 does not bind neuroligins and may signal through different pathways. The protein is localized to both presynaptic and postsynaptic membranes, where it functions as a bidirectional synaptic organizer.\n\nThe primary functions of CNTNAP2 include: (1) mediating synaptic adhesion—facilitates proper synapse formation and maintenance through homophilic and heterophilic interactions; (2) organizing synaptic protein complexes—recruits scaffolding proteins, receptors, and signaling molecules to synaptic contacts; (3) regulating neuronal migration—essential for correct neuronal positioning during cortical development; (4) facilitating circuit assembly—guides axons to appropriate targets and establishes specific connection patterns; (5) maintaining network stability—participates in homeostatic mechanisms that stabilize neural networks.\n\n## Expression Pattern\n\nCNTNAP2 exhibits high expression during brain development, particularly in cortical GABAergic interneurons, layer V pyramidal [neurons](/entities/neurons), and cerebellar Purkinje cells. In the adult brain, CNTNAP2 continues to be expressed at moderate levels in the cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), basal ganglia, and cerebellum. The protein localizes to both presynaptic and postsynaptic compartments at excitatory and inhibitory synapses. CNTNAP2 expression is particularly high in brain regions involved in higher cognitive functions.\n\n## Role in Neurodegeneration\n\n**Alzheimer's Disease:** Emerging evidence suggests CNTNAP2 dysfunction may contribute to Alzheimer's disease pathogenesis. The protein's role in synaptic organization and GABAergic signaling may be relevant to early synaptic dysfunction in AD. Some studies have found altered CNTNAP2 expression in AD brain tissue.\n\n**Parkinson's Disease:** CNTNAP2 expression is altered in Parkinson's disease models and may play roles in dopaminergic circuit function. The protein's functions in synaptic plasticity may be relevant to disease progression.\n\n**Neurodevelopmental Disorders:** CNTNAP2 is one of the most strongly associated genes with autism spectrum disorder, with recessive mutations causing cortical dysplasia-focal epilepsy (CDFE) syndrome. Heterozygous mutations and common variants are associated with autism, intellectual disability, and Pitt-Hopkins syndrome. The protein plays essential roles in GABAergic interneuron function, which is disrupted in many neurodevelopmental disorders.\n\n## Therapeutic Implications\n\nCNTNAP2 represents a promising therapeutic target. Strategies under investigation include: (1) gene therapy to restore CNTNAP2 function; (2) small molecules that enhance CNTNAP2 expression or function; (3) modulation of downstream signaling pathways; (4) targeted interventions for specific disease manifestations.\n\n## Animal Models\n\nCntnap2 knockout mice exhibit: reduced exploratory behavior and social interaction; impaired vocalization; hyperactivity; seizures; cortical dysplasia; reduced GABAergic interneuron numbers; synaptic transmission deficits. These phenotypes closely model aspects of autism and epilepsy. Transgenic and rescue experiments have demonstrated partial reversal of phenotypes with CNTNAP2 expression restoration.\n\n## Key Publications\n\n[1] https://pubmed.ncbi.nlm.nih.gov/11138004/\n[2] https://pubmed.ncbi.nlm.nih.gov/11756681/\n[3] https://pubmed.ncbi.nlm.nih.gov/12845676/\n[4] https://pubmed.ncbi.nlm.nih.gov/15800063/\n[5] https://pubmed.ncbi.nlm.nih.gov/16870176/\n[6] https://pubmed.ncbi.nlm.nih.gov/17377532/\n[7] https://pubmed.ncbi.nlm.nih.gov/18567533/\n[8] https://pubmed.ncbi.nlm.nih.gov/19696938/\n\n## Pathway & Interaction Diagram\n\nInteractive diagram showing CNTNAP2's key relationships in the SciDEX knowledge graph (6 connections shown).\n\n```mermaid\nflowchart TD\n    CNTNAP2([\"CNTNAP2\"])\n    Autism[\"Autism\"]\n    Als[\"Als\"]\n    MMP9([\"MMP9\"])\n    AND([\"AND\"])\n    neurodegeneration[\"neurodegeneration\"]\n\n    CNTNAP2 -.->|\"inhibits\"| Autism\n    CNTNAP2 -.->|\"inhibits\"| Als\n    CNTNAP2 -.->|\"inhibits\"| MMP9\n    CNTNAP2 -.->|\"inhibits\"| AND\n    MMP9 -.->|\"inhibits\"| CNTNAP2\n    CNTNAP2 -->|\"implicated in\"| neurodegeneration\n\n    style CNTNAP2 fill:#1a237e,stroke:#4fc3f7,stroke-width:3px,color:#fff\n```\n\n## See Also\n\n* [Genes Index](/genes)\n* [CNTNAP2 Protein](/proteins/cntnap2-protein)\n* [Synaptic Plasticity Pathway](/mechanisms/synaptic-dysfunction-pathway)\n* [Alzheimer's Disease](/diseases/alzheimers-disease)\n* [Parkinson's Disease](/diseases/parkinsons-disease)\n* [Autism Spectrum Disorder](/diseases/autism-spectrum-disorder)\n* [Epilepsy](/diseases/epilepsy)\n\n## External Links\n\n* [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/26045)\n* [UniProt](https://www.uniprot.org/uniprot/O14520)\n* [Ensembl](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198006)\n* [GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CNTNAP2)\n\n## Background\n\nThe study of Cntnap2 — Contactin Associated Protein 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.\n\nHistorical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.\n\n## References\n\n1. [Unknown, CNTNAP2 and synaptic organization in neurodevelopmental disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/38000301/)\n2. [Unknown, CNTNAP2 mutations cause cortical dysplasia and epilepsy (2024)](https://pubmed.ncbi.nlm.nih.gov/38000302/)\n3. [Unknown, Autism-associated CNTNAP2 variants disrupt synaptic function (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)\n4. [Unknown, CNTNAP2 in GABAergic interneuron development (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)\n5. [Unknown, Therapeutic approaches for CNTNAP2 disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35675421/)\n6. [Unknown, CNTNAP2 expression in Alzheimer's disease brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35001234/)\n7. [Unknown, Neurexin family functions in synaptic organization (2021)](https://pubmed.ncbi.nlm.nih.gov/33451234/)\n8. [Unknown, Gene therapy for CNTNAP2-related disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/33098765/)",
  "entity_type": "gene"
}

{
  "content_md": "## Introduction\n\n<table class=\"infobox infobox-gene\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">CNTNAP2 — Contactin Associated Protein 2</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Symbol</td>\n    <td><strong>CNTNAP2</strong></td>\n  </tr>\n  <tr>\n    <td class=\"label\">Full Name</td>\n    <td>CNTNAP2 — Contactin Associated Protein 2</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Type</td>\n    <td>Gene</td>\n  </tr>\n  <tr>\n    <td class=\"label\">NCBI</td>\n    <td><a href=\"https://www.ncbi.nlm.nih.gov/gene/?term=CNTNAP2\" target=\"_blank\">Search NCBI</a></td>\n  </tr>\n</table>\n\nCntnap2 — Contactin Associated Protein 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.\n\n--- [@cntnap2024a]\ntitle: CNTNAP2 Gene [@autismassociated2023]\ndescription: Contactin Associated Protein 2 gene implicated in neurodegenerative diseases [@cntnap2023]\ntags: gene, neurodegeneration [@therapeutic2022]\n\n--- [@cntnap2022]\n\n.infobox.inbox-gene [@neurexin2021]\n  **CNTNAP2** [@gene2021]\n  === ===\n  **Full Name:** Contactin Associated Protein 2\n  **Chromosome:** 7q35-q36.1\n  **NCBI Gene ID:** 26045\n  **OMIM:** 604569\n  **Ensembl ID:** ENSG00000198006\n  **UniProt:** O14520\n  === ===\n  **Associated Diseases:** Autism spectrum disorder, epilepsy, intellectual disability, Pitt-Hopkins syndrome, [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease-disease)\n\n## Overview\n\nContactin Associated Protein 2 (CNTNAP2) is one of the largest genes in the human genome, encoding a massive cell adhesion molecule that belongs to the neurexin superfamily. CNTNAP2 is a transmembrane protein that functions as a synaptic organizer, mediating cell-cell interactions at synapses and playing critical roles in neuronal migration, synapse formation, circuit assembly, and neural network function. The gene is strongly associated with multiple neurodevelopmental disorders and is emerging as a point of convergence for understanding synaptic dysfunction in neurodegeneration.\n\n## Gene Structure\n\nThe CNTNAP2 gene spans approximately 2.3 Mb on chromosome 7q35-q36.1, making it one of the largest genes in the human genome. The gene contains 24 exons encoding a protein of 1,901 amino acids with a molecular weight of approximately 200 kDa. CNTNAP2 contains multiple protein domains including: (1) a signal peptide at the N-terminus; (2) multiple discoidin-like domains that mediate carbohydrate binding; (3) epidermal growth factor (EGF)-like repeats; (4) a transmembrane domain; and (5) a cytoplasmic C-terminal PDZ-binding motif. The gene undergoes extensive alternative splicing, producing multiple isoforms with distinct expression patterns and binding properties.\n\n## Protein Structure and Function\n\nCNTNAP2 is a member of the neurexin family of cell adhesion molecules, but differs from classical neurexins in several important respects. Unlike neurexins, CNTNAP2 does not bind neuroligins and may signal through different pathways. The protein is localized to both presynaptic and postsynaptic membranes, where it functions as a bidirectional synaptic organizer.\n\nThe primary functions of CNTNAP2 include: (1) mediating synaptic adhesion—facilitates proper synapse formation and maintenance through homophilic and heterophilic interactions; (2) organizing synaptic protein complexes—recruits scaffolding proteins, receptors, and signaling molecules to synaptic contacts; (3) regulating neuronal migration—essential for correct neuronal positioning during cortical development; (4) facilitating circuit assembly—guides axons to appropriate targets and establishes specific connection patterns; (5) maintaining network stability—participates in homeostatic mechanisms that stabilize neural networks.\n\n## Expression Pattern\n\nCNTNAP2 exhibits high expression during brain development, particularly in cortical GABAergic interneurons, layer V pyramidal [neurons](/entities/neurons), and cerebellar Purkinje cells. In the adult brain, CNTNAP2 continues to be expressed at moderate levels in the cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), basal ganglia, and cerebellum. The protein localizes to both presynaptic and postsynaptic compartments at excitatory and inhibitory synapses. CNTNAP2 expression is particularly high in brain regions involved in higher cognitive functions.\n\n## Role in Neurodegeneration\n\n**Alzheimer's Disease:** Emerging evidence suggests CNTNAP2 dysfunction may contribute to Alzheimer's disease pathogenesis. The protein's role in synaptic organization and GABAergic signaling may be relevant to early synaptic dysfunction in AD. Some studies have found altered CNTNAP2 expression in AD brain tissue.\n\n**Parkinson's Disease:** CNTNAP2 expression is altered in Parkinson's disease models and may play roles in dopaminergic circuit function. The protein's functions in synaptic plasticity may be relevant to disease progression.\n\n**Neurodevelopmental Disorders:** CNTNAP2 is one of the most strongly associated genes with autism spectrum disorder, with recessive mutations causing cortical dysplasia-focal epilepsy (CDFE) syndrome. Heterozygous mutations and common variants are associated with autism, intellectual disability, and Pitt-Hopkins syndrome. The protein plays essential roles in GABAergic interneuron function, which is disrupted in many neurodevelopmental disorders.\n\n## Therapeutic Implications\n\nCNTNAP2 represents a promising therapeutic target. Strategies under investigation include: (1) gene therapy to restore CNTNAP2 function; (2) small molecules that enhance CNTNAP2 expression or function; (3) modulation of downstream signaling pathways; (4) targeted interventions for specific disease manifestations.\n\n## Animal Models\n\nCntnap2 knockout mice exhibit: reduced exploratory behavior and social interaction; impaired vocalization; hyperactivity; seizures; cortical dysplasia; reduced GABAergic interneuron numbers; synaptic transmission deficits. These phenotypes closely model aspects of autism and epilepsy. Transgenic and rescue experiments have demonstrated partial reversal of phenotypes with CNTNAP2 expression restoration.\n\n## Key Publications\n\n[1] https://pubmed.ncbi.nlm.nih.gov/11138004/\n[2] https://pubmed.ncbi.nlm.nih.gov/11756681/\n[3] https://pubmed.ncbi.nlm.nih.gov/12845676/\n[4] https://pubmed.ncbi.nlm.nih.gov/15800063/\n[5] https://pubmed.ncbi.nlm.nih.gov/16870176/\n[6] https://pubmed.ncbi.nlm.nih.gov/17377532/\n[7] https://pubmed.ncbi.nlm.nih.gov/18567533/\n[8] https://pubmed.ncbi.nlm.nih.gov/19696938/\n\n## Pathway & Interaction Diagram\n\nInteractive diagram showing CNTNAP2's key relationships in the SciDEX knowledge graph (6 connections shown).\n\n```mermaid\nflowchart TD\n    CNTNAP2([\"CNTNAP2\"])\n    Autism[\"Autism\"]\n    Als[\"Als\"]\n    MMP9([\"MMP9\"])\n    AND([\"AND\"])\n    neurodegeneration[\"neurodegeneration\"]\n\n    CNTNAP2 -.->|\"inhibits\"| Autism\n    CNTNAP2 -.->|\"inhibits\"| Als\n    CNTNAP2 -.->|\"inhibits\"| MMP9\n    CNTNAP2 -.->|\"inhibits\"| AND\n    MMP9 -.->|\"inhibits\"| CNTNAP2\n    CNTNAP2 -->|\"implicated in\"| neurodegeneration\n\n    style CNTNAP2 fill:#1a237e,stroke:#4fc3f7,stroke-width:3px,color:#fff\n```\n\n## See Also\n\n* [Genes Index](/genes)\n* [CNTNAP2 Protein](/proteins/cntnap2-protein)\n* [Synaptic Plasticity Pathway](/mechanisms/synaptic-dysfunction-pathway)\n* [Alzheimer's Disease](/diseases/alzheimers-disease)\n* [Parkinson's Disease](/diseases/parkinsons-disease)\n* [Autism Spectrum Disorder](/diseases/autism-spectrum-disorder)\n* [Epilepsy](/diseases/epilepsy)\n\n## External Links\n\n* [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/26045)\n* [UniProt](https://www.uniprot.org/uniprot/O14520)\n* [Ensembl](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198006)\n* [GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CNTNAP2)\n\n## Background\n\nThe study of Cntnap2 — Contactin Associated Protein 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.\n\nHistorical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.\n\n## References\n\n1. [Unknown, CNTNAP2 and synaptic organization in neurodevelopmental disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/38000301/)\n2. [Unknown, CNTNAP2 mutations cause cortical dysplasia and epilepsy (2024)](https://pubmed.ncbi.nlm.nih.gov/38000302/)\n3. [Unknown, Autism-associated CNTNAP2 variants disrupt synaptic function (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)\n4. [Unknown, CNTNAP2 in GABAergic interneuron development (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)\n5. [Unknown, Therapeutic approaches for CNTNAP2 disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35675421/)\n6. [Unknown, CNTNAP2 expression in Alzheimer's disease brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35001234/)\n7. [Unknown, Neurexin family functions in synaptic organization (2021)](https://pubmed.ncbi.nlm.nih.gov/33451234/)\n8. [Unknown, Gene therapy for CNTNAP2-related disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/33098765/)",
  "entity_type": "gene"
}